Please assess the completion status of the following clinical trial:

Trial Title: Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~In accordance with the SPC. Most important criteria:~* Histology or cytology proven inoperable, locally advanced,metastatic or recurrent (stage IIIB/IV) NSCLC other than predominantly squamous cell histology~* First-line treatment is indicated~* No previous treatment with Bevacizumab~Exclusion Criteria:~In accordance with the SPC. Most important criteria:~* Hypersensitivity to the active ingredient or to any of the excipients~* Hypersensitivity to products derived from Chinese hamster ovary (CHO) cells or to other recombinant human or humanized antibodies~* Pregnancy~* Bevacizumab is contraindicated in the presence of untreated central nervous system metastases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab (Type: None): Participants with advanced (stage IIIB/IV) NSCLC other than predominantly squamous cell histology receiving Bevacizumab in accordance with the summary product characteristics (SPC) is observed.

Based on this trial design, predict the completion outcome and termination type (if applicable).